MedTrace Logo

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

NCT02054481 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2016-09-19

Study results available
· View outcomes & findings →

Summary

The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.

Conditions

Interventions

DRUG

BI 655066

Medium dose

DRUG

BI 655066

High dose

DRUG

Ustekinumab

DRUG

BI 655066

Low dose

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-11-30
Completion
2015-07-31

Countries

  • United States
  • Canada
  • Finland
  • France
  • Germany
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02054481 on ClinicalTrials.gov